A Novel Approach to Platinum-Resistant Ovarian Cancer: Results from the Elenagen Phase II Study (ESGO 2026)

April 13, 2026 A Novel Approach to Platinum-Resistant Ovarian Cancer: Results from the Elenagen Phase II Study (ESGO 2026) Dr. Gabriel Levin, gynecologic oncologist at the McGill University Health Centre, and Director of Oncology at CureLab Oncology Inc., recently presented new clinical findings at the 27th Congress of the European Society of Gynaecological Oncology (ESGO 2026) in Copenhagen, highlighting a promising therapeutic advance for women with platinum-resistant ovarian cancer (PROC). The oral presentation, titled Randomized Phase II Study of P62/Sqstm1-Encoding Plasmid (Elenagen) In Combination With Gemcitabine for Platinum-Resistant Ovarian Cancer (Abstract 274), detailed results from a randomized Phase II clinical trial e valuating the DNA-based therapy Elenagen (p62/SQSTM1-encoding plasmid) in combination with gemcitabine. Dr. Levin’s presentation took place on Feb 27, 2026. Share Related posts September 3, 2026 Hormone-resistant prostate and breast cancers added to clinical study based on encouraging preliminary results Read more Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment.

The release as fetched from its publisher. curelaboncology.com ↗